Pharmafile Logo

Conference research case study

How conference research was used to gauge reactions to new clinical data and measure the impact of a company’s presence at a leading industry event


Our client had recently conducted a series of clinical trials with its breakthrough cardiovascular product, resulting in outcomes data which had the potential to give it a more competitive edge and successfully differentiate it against their closest competitor.

Communication strategies and marketing messages were to be crafted using the outcomes data which our client planned to launch at the European Society of Cardiology (ESC) annual congress. As a result, our client wanted to understand in detail the impact of their data on physicians’ perceptions of them.

In addition, with medical conferences representing a considerable investment in terms of time and resources, research was required to provide an understanding of what different aspects of the ESC annual conference meant to our clients key customers and the overall impact of the company’s presence on company perception.

Find out how we helped our client: https://bit.ly/2KuGas1

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Free Thinking: Behavioural economics

Our Free Thinking white paper asks, does behavioural economic theory have a role to play in pharmaceutical market research?

Article: The Colombia Conundrum

Published in eye for pharma 30 January by Marc Yates

Ageing in China: The Implications for Healthcare

Published in eye for pharma 12 December by Marc Yates

Exploring MINT: Part 4 - Turkey

In the fourth and final of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in...

Getting to grips with Russia’s healthcare market

As a non-Russian, trying to understand the complexities of the multiple overlapping levels of Russia’s healthcare system can be baffling at times. Information is often inaccessible or data simply doesn't...

Exploring MINT: Part 3 - Nigeria

In the third of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Nigeria.

Exploring MINT: Part 2 - Indonesia

In the second of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Indonesia, with...

Free Thinking: Leveraging the ASEAN Market

If you can only research one ASEAN market, which one do you choose?Our Free Thinking paper investigates the opportunities for pharma in ASEAN and outlines the factors you need to...

Free Thinking: Biosimilars: Friend or foe to healthcare?

Our Free Thinking white paper looks at the opportunities for biosimilars and the threats to innovator biologics.